ArrePath today announced the appointment of Kevin Krause as President and Chief Executive.
;)
ArrePath today announced that it has been awarded a £1 million non-dilutive grant from PACE (Pathways to Antimicrobial Clinical Efficacy) in support of its efforts to develop a new class of antibiotics designed to address multidrug-resistant (MDR) infections, a growing global health threat.
ArrePath will be presenting at the BioNJ BioPartnering event on May 14th at Liberty Science Center in Jersey City, NJ!
Join us in the Delta Lab at 10:50 AM – 12:10 PM.
The BioNJ BioPartnering Conference is co-sponsored by J.P. Morgan, J&J Innovation, and Morgan Lewis, and hosted by the Jersey City Economic Development Corporation.
ArrePath will be attending the 34th European Congress of Clinical Microbiology & Infectious Diseases, which will take place in Barcelona, Spain from April 27-30.
ArrePath is pleased to be presenting at @MassBio 2024 Align
Summit w/ insights by @McKinsey & @LocustWalkPtrs. Register for a day full of partnering opps. w/
investors, panels & presentations from early-stage #Biotech and emerging AI/ML companies.
https://www.massbio.org/align
ArrePath will be attending the 2024 Gordon Research Conference on New Antibacterial Discovery and Development, March 17-22, 2024, Ventura CA.
ArrePath will be attending the 8th AMR Conference, March 6-7, 2024 in Basel Switzerland.
Kurt Thorn, ArrePath’s Chief Technology Officer, will be speaking at the Biotech Showcase on January 9, 2024.
The world’s largest AMR Conference for all stakeholders combatting Anti-Microbial Resistance
07-19-2023 
We look forward to the World AMR Conference September 7-8 in Philadelphia, where our CEO, Lloyd Payne will be attending.
ArrePath will be attending the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance happening on Sept. 19-22, 2023 in Boston, Mass. where you’ll hear the latest updates in drug development and antimicrobial resistance.